Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism (for specialized target groups only)

If approved, rivaroxaban 10 mg once daily will provide an additional treatment option alongside the already approved rivaroxaban 20 mg once-daily dose / Risk of recurrent thrombosis is up to 10% in the first year if anticoagulation therapy is stopped / Application to FDA supported by data from the EINSTEIN CHOICE study
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news